Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR1 amp AZD4547 lung large cell carcinoma sensitive detail...
FGFR1 positive AZD4547 + AZD8055 lung large cell carcinoma sensitive detail...
FGFR1 positive AZD4547 + Vistusertib lung large cell carcinoma sensitive detail...
FGFR1 positive AZD4547 + Sirolimus lung large cell carcinoma sensitive detail...
TP53 R175L NSC319726 lung large cell carcinoma sensitive detail...
TP53 wild-type NSC319726 lung large cell carcinoma resistant detail...
FGFR1 amp ODM-203 lung large cell carcinoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02185690 Phase I Binimetinib + Carboplatin + Pemetrexed Disodium A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung Completed CAN 0
NCT03591731 Phase II Nivolumab Ipilimumab + Nivolumab Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (NIPINEC) Active, not recruiting FRA 0
NCT03976518 Phase II Atezolizumab Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial) (CHANCE) Completed ITA 0
NCT04748419 Phase Ib/II Durvalumab Safety and Efficacy of Consolidative Hypofractionated Radiation Therapy (hfRT) for Boosting the Residual Primary Lung Cancer With Durvalumab Recruiting USA 0
NCT05198830 Phase II Cisplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium + TRC102 Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer Recruiting USA 0
NCT05680922 Phase I LB2102 DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer Recruiting USA 0
NCT05860296 Phase Ib/II Pembrolizumab + SLC-391 Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers Recruiting USA | CAN 0
NCT05879978 Phase Ib/II BI 764532 + Ezabenlimab A Study to Test How Well Different Doses of BI 764532 in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 Recruiting FRA | DEU | BEL 1
NCT06393816 Phase II Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Etoposide FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum (FIRST-NEC) Not yet recruiting FRA 0